Psychemedics

Psychemedics AAQS

The The AAQS of Psychemedics (PMDI) as of Oct 29, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

Psychemedics has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Psychemedics in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Psychemedics AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2017
1.00 USD
Jan 1, 2018
1.00 USD
Jan 1, 2019
1.00 USD
Jan 1, 2020
1.00 USD
Jan 1, 2021
1.00 USD
Jan 1, 2022
1.00 USD
Jan 1, 2023
1.00 USD
Jan 1, 2024
1.00 USD
The Psychemedics AAQS history
YEARAAQSYoY
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Psychemedics Stock analysis

What does Psychemedics do? Psychemedics Corp provides drug testing services analyzing hair samples for drug presence, offering historical usage patterns and approximate drug intake levels. The company charges customers a per-unit fee for each tested sample, including training for sample collection and storage of positive results. Their primary service targets clients needing drug testing solutions, particularly in sectors requiring regular monitoring of substance use. The firm's technology focuses on hair analysis to deliver detailed insights into drug consumption over time. Psychemedics Corp's revenue model is based on per-unit testing fees, with services including sample collection training and storage of positive samples. Customers pay for each sample tested, leveraging the company's hair analysis technology to monitor drug use patterns. The business operates within the drug testing services segment, serving clients who require reliable and historical data on substance abuse. The company's drug testing services are designed for customers seeking detailed historical data on drug use, with results indicating both the amount ingested and usage patterns over time. Psychemedics Corp generates income through fixed fees per sample tested, covering the full service including sample collection training and positive sample storage. Their focus remains on delivering accurate, long-term drug usage insights through hair analysis. Psychemedics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Psychemedics stock

The AAQS of Psychemedics is 1 in 2024.

On Eulerpool you can find the complete historical development of The AAQS Psychemedics since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Psychemedics

All Key Metrics — Psychemedics